Quantgene has developed a method for Deep Human Genome sequencing which allows the visualisation of mutational patterns of disease down to a single molecule. The GRIFFIN Deep Genomics Platform enables the profiling of cfDNA in a patient’s blood with near-absolute precision. This helps inform early cancer detection, prediction of disease onset as well as non-invasive treatment monitoring for longer healthier lives.